← Back to Search

Nucleotide Reverse Transcriptase Inhibitor

PMPA Prodrug for HIV

Phase 1
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have HIV infection, as indicated by seropositivity for HIV infection (ELISA and Western blot), positive HIV culture, or positive plasma HIV RNA.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing the safety of a new drug for HIV, as well as how well it works and how it is metabolized.

Who is the study for?
This trial is for HIV-infected patients with a CD4 cell count of 200 or more cells/mm3 and plasma HIV RNA of at least 10,000 copies/ml. Participants must have a life expectancy of over 12 months and not be on certain medications like antiretrovirals or drugs that affect the kidneys. They should also not have serious infections, significant heart disease, hepatitis B, certain cancers, or engage in substance abuse.Check my eligibility
What is being tested?
The trial tests PMPA prodrug's safety and effectiveness when taken orally by HIV patients. It looks at how the body processes the drug (pharmacokinetics), its ability to boost immune function (increase CD4 counts), and reduce viral load (decrease in HIV RNA) after single doses and daily use for four weeks.See study design
What are the potential side effects?
While specific side effects are not listed here, participants will be monitored for any adverse reactions to PMPA prodrug during single dose administration as well as throughout the daily dosing over a period of four weeks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am HIV positive, confirmed by a test.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,077 Previous Clinical Trials
836,890 Total Patients Enrolled

Media Library

PMPA Prodrug (Nucleotide Reverse Transcriptase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00002396 — Phase 1
Human Immunodeficiency Virus Infection Research Study Groups:
Human Immunodeficiency Virus Infection Clinical Trial 2023: PMPA Prodrug Highlights & Side Effects. Trial Name: NCT00002396 — Phase 1
PMPA Prodrug (Nucleotide Reverse Transcriptase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002396 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants aged 55 or older eligible to enroll in the experiment?

"This clinical trial has established that only those aged 18-60 are eligible for enrollment. For individuals below the age of consent, there are 108 studies available; whereas, 353 tests exist for patients over 65 years old."

Answered by AI

Are there any eligibility criteria for participating in this clinical experiment?

"This medical research requires 60 participants ranging from 18 to 60 years old, diagnosed with HIV. Additionally, they must have a CD4 cell count of 200 or more cells/mm3 within 28 days prior to study entry., plasma HIV RNA of 10,000 copies/ml and a life expectancy exceeding 1 year."

Answered by AI

What safety precautions have been taken to ensure the well-being of subjects using this treatment?

"Due to the limited clinical evidence that supports safety and efficacy of this treatment, it receives a score of 1 on our risk-assessment scale."

Answered by AI
~40 spots leftby Mar 2025